The paper reports electroporation of CRISPR-Cas9 RNPs into primary human B cells to achieve protein-level knockout (e.g., CD22) and functional phenotypes (e.g., STAT3→reduced IL-21–driven plasma cell differentiation), plus HDR-based knock-in with ssODNs (MS4A1/CD20) at reported efficiencies >10% reads.
Key caveat: the paper emphasizes editing efficiency but provides limited detail here on off-target profiling and long-term edited-cell fate, which limits how confidently one should generalize beyond the tested culture conditions.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.